pharma · Non-squamous Cell Non-Small Cell Lung Cancer
Henan Provincial People's Hospital
Henan Provincial People's drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Henan Provincial People's drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Development asset linked to Henan Provincial People's in public FDA and regional records. Molecular target: Platelet-derived growth factor receptor beta.
US regulatory status: approved. Molecular target: Dihydrofolate reductase.